Infection with varicella-zoster virus (VZV) in oncology patients can result in severe disease with an increased risk of morbidity and mortality [1, 2] . Among patients on cancer chemotherapy, only nonimmune persons are considered to be susceptible to varicella [1] . We present a case of varicella in a child with leukemia that occurred despite immunity as defined by 2 doses of varicella vaccine and documentation of positive VZV immunoglobulin G titer before initiation of chemotherapy.
A 12-year-old male with pre-B cell acute lymphoblastic leukemia (ALL) diagnosed 13 months earlier was admitted to the hospital with complaints of fever and a rash. Sixteen days before hospital admission, he had household contact with a live-in nanny with localized herpes zoster ("shingles") on a lower extremity. She left the home 2 days after the appearance of her rash and returned after her lesions had crusted. Postexposure varicella zoster immune globulin (VZIG) was not administered. He had received varicella vaccine at ages 1 and 7 years. Serology for varicella-zoster virus (VZV) immunoglobulin G, performed before administration of any blood product, was positive (Chemiluminescence Immunoassay [DiaSorin, Stillwater, MN] value, 182.2 index; positive, >165 index; equivocal, 135-165 index; negative, <135 index) before initiation of chemotherapy. Nine months after diagnosis of ALL, varicella serology was repeated and was negative (Chemiluminescence Immunoassay value, 133.1 index).
He was in the maintenance phase of chemotherapy protocol AALL1131 and was receiving 6-mercaptopurine, methotrexate, vincristine, and prednisone. He was receiving 70% of the total prescribed dose of 6-mercaptopurine due to a history of elevated hepatic transaminases and 60% of the total prescribed dose of vincristine due to a history of neuropathy. Eight days before admission, he had an elevated aspartate aminotransferase (AST) of 159 units per liter, alanine aminotransferase (ALT) of 302 units per liter, and total bilirubin elevated to a value of 1.4 milligrams per deciliter. Four days before admission, he completed a 5-day course of prednisone at a dosage of 40 mg/m 2 per day (1.16 milligrams per kilogram per day). Two days before admission he had an ambulatory visit, and at that time he had neither fever nor rash. Laboratory testing showed elevated values for AST of 383 units per liter, ALT of 593 units per liter, and total bilirubin of 1.8 milligrams per deciliter. Methotrexate and 6-mercaptopurine were withheld. On the night before his hospital admission, his mother noted a red papule on his right thigh. Over the next few hours, he developed 2 additional lesions with a similar appearance on his abdomen. Review of systems was otherwise negative.
Physical examination revealed a well appearing boy in no distress. His vital signs were notable for a temperature of 38.1°C and pulse rate of 114 per minute. There were 3 vesicular lesions on an erythematous base, 1 on his right thigh and 2 on the abdomen. He had a central venous catheter in the left upper chest. The remainder of his physical examination was within normal limits. Within a few hours, additional lesions with a similar appearance developed on his abdomen and upper back.
Initial laboratory evaluation revealed a white blood cell count of 3100 cells/µL, with 80% segmented neutrophils, 2% band neutrophils, 8% lymphocytes, 5% monocytes, 4% eosinophils, and 1% metamyelocytes. The hemoglobin was 14.9 grams per deciliter and platelet count was 132 000 cells/µL. Serum sodium was 131 mEq/L, AST and ALT were 451 and 805 units per liter, respectively, and total bilirubin was 2.3 milligrams per deciliter.
Treatment with intravenous acyclovir was initiated at a dose of 30 mg/kg per day, and he received 1 dose of intravenous ceftriaxone. During the first 2 days of hospitalization, he had fever, chills, rigors, nausea, and anorexia. Multiple additional lesions that were pruritic appeared on his trunk, extremities, head, and scalp with a total of approximately 50 lesions. Hepatic transaminases peaked on hospital day 2 with AST of 647 units per liter and ALT of 913 units per liter and subsequently declined but remained above normal. Total bilirubin normalized on hospital day 3. He developed mild neutropenia (1300 cells/µL) on hospital day 2, and intravenous antibiotics were re-initiated. His platelet count nadir was 96 000 cells/µL on hospital day 4. After hospital day 4, there were no new lesions and the existing lesions began to crust. On hospital day 7, he received granulocyte colony-stimulating factor. He completed 7 days of intravenous acyclovir with clinical resolution of symptoms and signs.
Fluid from a vesicle grew VZV in cell culture, and VZV deoxyribonucleic acid was detected using a polymerase chain reaction (PCR)-based assay (Argene Herpes Consensus Generic Assay; Biosoft, Varilhes, France). By real-time PCR testing, the fluid was demonstrated to contain wild-type VZV by the New York State Department of Health Wadsworth Center Laboratory in Albany, New York.
DISCUSSION
Varicella infection can cause morbidity and mortality in oncology patients. Untreated varicella infection in children with cancer has been associated with a mortality of approximately 7% [2] . Our patient had laboratory documentation of varicella by both growth of VZV in viral culture and detection of VZV by nucleic acid amplification, and the infection was caused by a wild-type strain, not vaccine virus. Infection occurred despite receipt of 2 doses of varicella vaccine before diagnosis of ALL. In addition, he had serologic evidence of immunity before initiation of chemotherapy. Either receipt of 2 doses of vaccine or serologic evidence of immunity fulfills the Centers for Disease Control and Prevention and the 2015 Red Book's criteria for evidence of immunity to varicella [1] , yet he developed varicella. Postexposure immunoprophylaxis with VZIG is recommended for immunocompromised patients without evidence of immunity to varicella with significant exposure to varicella or herpes zoster [1] . Passive immunization with VZIG may prevent or modify the course of varicella [1] . Our patient had 2 forms of evidence of immunity to varicella [1] . Therefore, postexposure immunoprophylaxis was not administered. This case challenges the concept that protective immunity is durable in an immunocompromised host who was classified as immune before initiating immunosuppressive treatments.
Children with malignancy may develop varicella despite a positive serologic status before initiating chemotherapy [2] [3] [4] [5] . Commercial assays for VZV serology may not reliably measure protective VZV antibody in vaccinated children. Furthermore, these assays may also result in false-positive results [1] . Including the current case, a literature review The index case was a boy with ALL. All affected patients lived in a group housing facility for cancer patients.
identified varicella disease in 14 children previously seropositive for VZV (Table 1 ) [2] [3] [4] [5] . All were hospitalized, and there was 1 varicella-associated death. The fatal case was a 4-yearold girl with ALL who had received 1 dose of varicella vaccine and had a positive VZV serology at the time of ALL diagnosis but died from varicella-associated multiorgan failure [4] . The current case is the first in which the patient developed varicella disease despite documentation of vaccination with 2 doses of varicella vaccine and serologic evidence of immunity before chemotherapy. Five additional oncology patients developed varicella despite receipt of at least 1 dose of varicella vaccine and VZV positive serology before chemotherapy (Table 1) . Therefore, receipt of 1 or 2 doses of varicella vaccine and seropositivity before chemotherapy may be insufficient evidence for persistent immunity to varicella during cancer chemotherapy.
Severe varicella has been reported in association with recent use of systemic corticosteroids [1, 2] . A retrospective study of varicella in children with ALL examined the relationship between recent corticosteroid therapy and severity of varicella infection. They found that prednisone therapy during the VZV incubation period was associated with an increase in the risk of developing severe infection [2] . Our patient received corticosteroids during the VZV incubation period, the 4-year-old girl who died from varicella infection had received 5 days of dexamethasone 13 days after varicella exposure [4] , and all 9 ALL patients on maintenance chemotherapy in the report by Manley et al [2] had received 5 days of oral dexamethasone during the 28 days before diagnosis of varicella. As recommended by Hill et al [6] , corticosteroid therapy should be deferred during the VZV incubation period in VZV-exposed ALL patients, with the exception of the exposure occurring during induction chemotherapy.
CONCLUSIONS
The use of postexposure immunoprophylaxis should be considered for highly immunocompromised patients with significant exposure to VZV, despite a positive serologic test for varicella antibodies before chemotherapy or a history of 2 doses of varicella vaccination. The limitations of using serology as a surrogate for immunity are described in the literature. However, if there are additional reports of varicella disease occurring in immunocompromised patients despite a history of 2 doses of vaccine, then the recommended indications for administering VZIG should be modified. Finally, for such exposed patients, clinicians should strongly consider avoiding or reducing corticosteroid therapy during the 21 days after exposure, if clinically feasible. 
